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With the growing demand for personalized medicine and medical devices, the impact of on-31 
demand triggerable (e.g., via magnetic fields) drug delivery systems increased significantly in 32 
recent years. The three-dimensional (3D) printing technology has already been applied in the 33 
development of personalized dosage forms because of its high-precision and accurate 34 
manufacturing ability. In this study, a novel magnetically triggerable drug delivery device 35 
composed of a magnetic polydimethylsiloxane (PDMS) sponge cylinder and a 3D printed 36 
reservoir was designed, fabricated and characterized. This system can realize a switch between 37 
“on” and “off” state easily through the application of different magnetic fields and from 38 
different directions. Active and repeatable control of the localized drug release could be 39 
achieved by the utilization of magnetic fields to this device due to the shrinking extent of the 40 
macro-porous magnetic sponge inside. The switching “on” state of drug-releasing could be 41 
realized by the magnetic bar contacted with the side part of the device because the times at 42 
which 50%, 80% and 90% (w/w) of the drug were dissolved are observed to be 20, 55 and 140 43 
min, respectively. In contrast, the switching “off” state of drug-releasing could be realized by 44 
the magnetic bar placed at the bottom of the device as only 10% (w/w) of the drug could be 45 
released within 12 h. An anti-cancer substance, 5-fluorouracil (FLU), was used as the model 46 
drug to illustrate the drug release behaviour of the device under different strengths of magnetic 47 
fields applied. In vitro cell culture studies also demonstrated that the stronger the magnetic field 48 
applied, the higher the drug release from the deformed PDMS sponge cylinder and thus more 49 
obvious inhibition effects on Trex cell growth. All results confirmed that the device can provide 50 
a safe, long-term, triggerable and reutilizable way for localized disease treatment such as cancer. 51 
    52 
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1. Introduction 58 
The objective of drug delivery systems is to provide predetermined drug release profiles 59 
ensuring optimal distribution and absorption of pharmaceutical compounds, which enhance 60 
therapeutic effectiveness and minimize side effects by offering a safer, more convenient, and 61 
efficient drug administration in humans with enhanced patient compliance [1][2]. 62 
Predetermined drug release profiles could be achieved by optimizing suitable drug delivery 63 
systems (DDSs) as such enhanced efficacy, safety, and patient compliance may be realized 64 
through optimal drug distribution and absorption in the targeted location at the (sub)cellular 65 
level [2][3]. However, it has been difficult for conventional drug delivery system to maintain 66 
drug concentration level within the narrow therapeutic concentration window for avoiding 67 
ineffectiveness (underdose) or toxicity (overdose), and it is often impossible to modify the drug 68 
release from these systems after administration [1][4][5]. Additionally, it may not always be 69 
appropriate for untunable monotonic drug release to be applied in some disease treatments 70 
which require variable release kinetics (including cancer, diabetes, pain, and myocardial 71 
infarction) [1][4]. Also, drugs are needed to be administered multiple times or continuously for 72 
achieving a long-acting drug release profile in some circumstances [4]. This may lead to 73 
patients’ discomfort or inconvenience and even the addition of external devices. Therefore, it 74 
is important to design a drug delivery system, which can modulate drug release in terms of 75 
time, rate, and location. Such a drug delivery system would show considerable advances in 76 
delivering drugs, like painkillers, hormones, and chemotherapeutic agents [1]. 77 
Triggerable drug delivery systems (TDDSs), capable of releasing drug through applying 78 
external physical signals (such as magnetic field, ultrasound, pH, enzymes, temperature, 79 




pharmaceutical sciences [1][6][7]. Such systems containing a large amount of drug can present 81 
remote, noninvasive, tunable, and reliable switching of therapeutic compound flux [4]. Hence, 82 
spatiotemporal management of drug availability could be realized through these triggerable 83 
drug delivery systems by the physicians or patients with the utilization of either the interaction 84 
between a ‘responsive’ material and the surrounding environment or a remotely controllable 85 
activation device [1][5][8]. Also, these systems loaded with a large amount of drug can achieve 86 
multiple dosing after a single administration through repeatable triggering [1]. However, there 87 
are still some limitations, like low controllability because of an initial burst release or a drug 88 
leakage via diffusion, difficulty in disposing of the systems after therapy, and increasing 89 
toxicity-associated risks due to the possible degradation of the matrix and the reduction of 90 
stability and reliability of the systems [1][5]. 91 
Implantable reservoir-based devices have been designed to overcome these limitations 92 
efficiently [9]. Targeted therapy could be achieved through these devices at different length 93 
scales with high anatomical variability [10]. The performing procedure and working 94 
environment will affect the features, sizes, and operation mechanisms significantly [5]. Herein, 95 
it is highly desirable to fabricate untethered macroscale triggerable drug delivery systems with 96 
low cost, simple preparation, facile operation, simplified structural morphology, and the ability 97 
to move through body channels and perform on-demand drug administration [5][11].  98 
Although several external stimuli have been studied in TDDSs, controlled drug targeting 99 
through magnetic actuation is still one of the principal approaches because of many advantages, 100 
such as instantaneous and reversible response, remote actuation, non-destructive and high 101 
controllability, which are especially attractive for biomedical fabrication where the noncontact 102 
feature is particularly necessary in vivo environment with absolute safety [3][12][13]. Those 103 
magnetic systems also play an important role in cancer research due to the superior ability in 104 
chemotherapy by realizing: (1) selective delivery of the maximum fraction of anti-cancer 105 
molecules to the desired site without any increase in side effects to normal cell; (2) prior 106 
distribution of anti-cancer drug to targeted cells; (3) stable systemic drug concentration and (4) 107 
elimination of normal tissue clearance with the application of external magnetic field [3]. 108 




carriers, including Fe3O4 particles [7][14], NdFeB powders [5] and carbonyl iron (CI) powders 110 
[12][13]. With the addition of magnetic enclosures, these magnetically responsive systems can 111 
move and deform due to applied magnetic fields [15]. Furthermore, with the manipulation of 112 
external permanent magnets, magnetic triggering drug delivery systems have the ability to 113 
remote locomotion through biological tissues in real-time because magnetic fields can transmit 114 
high force or torques wirelessly with multiple degrees of freedom to medical robots [5][16]. 115 
In recent years, personalized medicine has attracted increasing attention as it can provide 116 
patients with a superior treatment with a comprehensive consideration of their own 117 
pharmacogenomics, anatomical, and physical conditions [17]. It is reported that the 118 
inappropriate dosing or dosing combination has become the main reason for adverse effects 119 
from drug therapy [18]. This leads to an increased demand for a tailored method of dosage 120 
forms to suit patient needs instead of “One-size-fits-all” [18][19]. 121 
To address these challenges, three-dimensional printing (3DP) technology has been applied 122 
successfully because traditional DDSs cannot fulfil such criteria [17][19]. Because of its 123 
potential in personalized medicine, its applications in medical devices, implants, tissue 124 
engineering, and pharmaceutical dosage forms have attracted a great deal of attention [18]. 125 
This technology can achieve detailed and flexible spatial composition, and provide more 126 
available starting materials (like colloidal inks, bio-inks, and polymers) for the unprecedented 127 
complex and precise manufacture of 3D DDSs [2][20]. Various techniques, namely powder-128 
based (PB), stereolithography (SLA), selective laser sintering (SLS), inkjet printing and fused 129 
deposition modelling (FDM) have been explored in the pharmaceutical applications [19]. 130 
Among them, FDM 3DP has gained the most attention due to its cost-effective, time-saving 131 
and versatile modalities of producing sophisticated solid objects [18][19]. 132 
Polylactic acid (PLA) is the most common material used for FDM because it is a non-toxic, 133 
renewable, thermoplastic, biodegradable and biocompatible polymer [20][21]. Additionally, its 134 
suitable properties like high mechanical strength, low coefficient of thermal expansion and 135 
processability for extrusion applications make this material ideal for pharmaceutical and 136 
biomedical applications [21]. Furthermore, various polymers, such as Pluronic, poly(vinyl 137 




addition of active pharmaceutical ingredients (APIs) to the final composite material in 139 
healthcare applications [20][21][22][23]. 140 
In this study, a magnetic-field triggerable drug delivery system with a 3D-printed reservoir and 141 
magnetic PDMS sponges was designed and characterized. This device can achieve highly 142 
precise and dynamic administration of drugs in an active and instant manner with only a 143 
permanent magnet.  144 
 145 
2. Materials and Methods 146 
2.1. Materials 147 
A SYLGARD® 184 Silicone Elastomer prepolymer (Sylgard 184A, Mw ≈ 22 000 g·mol
-1) and 148 
the thermal curing agent (Sylgard 184B, Mw ≈ 15 000 g·mol
-1) were purchased from Dow 149 
Corning. Carbonyl iron (CI) powder with purity ≥ 97% was purchased from Sigma-Aldrich 150 
(Germany). The white granulated sugar was purchased from Sainsbury’s (UK). The model 151 
anticancer drug 5-fluorouracil (FLU) with purity > 98% was purchased from Hangzhou 152 
Longshine Bio-tech Co., Ltd. (Hangzhou, China). The PLA filament (FilaPrint® premium PLA, 153 
1.75 mm) was purchased from 3D FilaPrint Ltd. (Essex, UK). All chemicals used were of 154 
analytical or food grade and used as received. 155 
 156 
2.2. Preparation of PDMS Sponges 157 
An eco-friendly sugar templating method was applied to fabricate porous magnetic sponges in 158 
this study because the commercially available household sugar which is used as the mould 159 
could be removed easily through immersion in water afterwards [24]. Around 15 g sugar was 160 
thoroughly mixed with 0.5 mL water and pressed firmly in a Petri dish (diameter = 5 cm). Then 161 
the Petri dish was placed in a convection oven (Memmert, UF110, Schwabach, Germany) at 162 
50°C for around 1 h to dry the sugar for achieving a mould of connected sugar particles [1]. 163 
PDMS prepolymers and curing agents were mixed by a weight ratio of 10:1. Then the magnetic 164 
microparticles were blended with the well-mixed PDMS solution at different magnetic 165 
particle:PDMS weight ratios of 0:10 (0 w/w %), 3:10 (30 w/w %), 5:10 (50 w/w %), 10:10 166 




mould and then the mixture was infiltrated into the sugar template because of capillary force 168 
[24]. The Petri dish was placed in the oven again at 70°C for 3 h for the curing process. Finally, 169 
the cured blend was immersed in water to dissolve the sugar completely. After the removal of 170 
the sugar templates, 3D eco-friendly interconnected microporous PDMS sponges were formed. 171 
 172 
2.3. Preparation and Characterization of the Reservoir 173 
2.3.1. Design of the Reservoir 174 
The model reservoir was designed using Solidworks (2017 SP5, Waltham, MA, USA) and 175 
converted to a stereolithography file (.stl). For the ease of printing operation, the geometry of 176 
the 3D printed reservoirs was selected as cylinder shape because of the large surface area in 177 
contact with the building plate [25]. The currently optimized design was flat cylindrical with a 178 
smoothed edge and consisting of two parts: top and bottom (Figure 1 A and B). The diameter 179 
and height of the reservoir are 19 mm and 7 mm respectively. The diameter and height of the 180 
hollow space for sponges are 12.5 mm and 5 mm respectively. In addition, there is a small 181 
aperture (diameter = 1.5 mm) at the centre of the top part surface. 182 
 183 
 184 
  weight (g) diameter (mm) height (mm) 
top part 0.811±0.003 19.367±0.045 6.153±0.069 
bottom part 0.980±0.005  19.385±0.029 6.662±0.050 
whole reservoir 1.791±0.007 19.385±0.029 7.764±0.061 
 Figure 1. Stereolithography images of (A) the bottom part and (B) the top part of the reservoir. 185 
(C) The printing process of the PLA reservoir with Robo R2. (D) Macroscopic appearance of 186 




assembled 3D-printed PLA reservoir loaded with 100% CI/PDMS sponge and drug solution. 188 
Dimensions and weight of the 3D printed reservoir are also shown (𝑛 = 6). The dimention and 189 
weight of each part was also added in this figure.  190 
 191 
2.3.2. FDM 3DP of the Reservoir 192 
Printing was performed in a Robo R2 (San Diego, CA, USA) using a nozzle with a diameter 193 
of 0.4 mm for printing PLA 1.75 mm 3D printer filaments. The following settings were 194 
employed: the printing temperature (Tprint) was set at 195 °C, Tplatform = 60 °C, infill pattern = 195 
light, layer height = 0.1 mm. 196 
  197 
2.3.3. Appearance, dimensions, and microstructure of the reservoir 198 
Samples prepared by FDM were photographed and were visually investigated. The diameter 199 
and height of the 3D printed reservoirs were measured with a vernier calliper. The radial 200 
expansion coefficient (𝐸𝑟) of filaments was calculated according to Eq. 1, where 𝐷𝑓 and 𝐷0 201 




× 100%                           (Eq. 1) 203 
The printed reservoir (top and bottom part) was examined by Jeol JMS 820 scanning electron 204 
microscopy (Freising, Munich, Germany) at the accelerating voltage of 3 kV. The samples were 205 
mounted on an aluminium stub using adhesive carbon tape and were sputter-coated with gold 206 
under vacuum (Edwards S-150 sputter coater, Edwards High Vacuum Co. International, Albany, 207 
NY, USA). 208 
 209 
2.4. Assemble and Drug Loading of the TDDS 210 
2.4.1. Preparation of Drug Solution 211 
The model drug in this study, 5-fluorouracil (FLU), is sparingly soluble in water and slightly 212 
soluble in ethanol [27], so it is necessary to design how to increase the dose of FLU loaded into 213 
the device. However, the solubility of 5-fluorouracil can be affected significantly by 214 
temperature as it can increase more than 12-fold by enhancing the temperature between 25 and 215 
200°C under the constant pressure of 5.1 MPa [28]. Additionally, Singh et al. point out that 5-216 




the temperature of the solution was increased in the preparing process. 218 
 219 
2.4.2. Device Integration and Assembly 220 
The sponge cylinders which can fit the shape of the hollow space of the reservoir bottom will 221 
be cut and then immersed into the drug solution. After the sponge cylinder absorbed enough 222 
drug solution, it was taken out and placed into the bottom hollow. Then the two parts of the 223 
reservoir were closed tightly. 224 
 225 
2.4.3. Drug Loading of the Device 226 
By comparing the weight change of the device before and after the drug loading process, the 227 
amount of drug loaded into the device could be calculated every time afterwards because the 228 
weight ratio of the drug to the solution is constant. 229 
 230 
2.5. Dissolution Test under Sink Conditions 231 
In vitro dissolution tests under sink conditions were performed with a US Pharmacopeia (USP) 232 
type Ⅰ basket or type Ⅱ  paddle apparatus (708-DS Dissolution Apparatus, Agilent 233 
Technologies, USA) in 900 mL of PBS (pH 6.8) at 37 ± 0.3 °C with the paddle speed of 100 234 
rpm according to different designed modes (Figure 2). The drug concentration in the dissolution 235 
medium was measured automatically using Cary 60 UV-Vis (Agilent Technologies, USA) at a 236 
wavelength of 265 nm in a 1 cm cell versus a blank solution consisting of PBS (pH 6.8). All 237 
samples were run in triplicate (n = 3). Then the release profile could be plotted as a percentage 238 
of cumulative drug release versus time. The preliminary results showed that the materials used 239 
in 3D printing such as PLA does not interfere with drug detection and UV absorbance. The 240 
standard curve was prepared in the concentration of 0.625-20 μg/mL (𝐴 = 0.0514𝐶 + 0.002, 241 
𝑅2=0.9995) where 𝐴 is the absorbance and 𝐶 is the concentration (μg/ml). 242 
 243 
To study the effect of the position of magnet versus device containing the sponge, various 244 
modes were employed. In Mode 1 (Figure 2A), the device was lying on the magnet. In Mode 245 




magnet. In Mode 4 (Figure 2D), the device was placed in the basket without magnet. 247 
 248 
Figure 2. Various modes for comparing the drug release from the device. (A) Mode 1: the 249 
device was laid flat on the magnet; (B) Mode 2: the device with no magnets; (C) Mode 3: the 250 
device was placed vertically on the magnet; (D) Mode 4: the device was placed in the basket 251 
without magnets. 252 
    253 
Neodymium grade N42 magnets were applied for providing different magnetic flux densities 254 
with a distance of 5 mm for the device during the dissolution testing (Table 1).  255 
 256 
Table 1. Dimensions of magnets used in the current studies to provide different magnetic flux 257 
densities with 5 mm distance between the specimen and magnets 258 
Magnets A* B C D 
diameter (mm) 19.5 19.5 21.5 19.5 
thickness (mm) 2.5 2.5 5.5 9.5 
magnetic field (mT) 110 150 204 355 
*The effect of this magnet was not further investigated 259 
 as it did not show a significant deformation on sponges 260 
 261 
The similarity factor (𝑓2) in Eq. 2 was developed by Moore and Flanner as a model-independent 262 
mathematical method to analyze the closeness among these dissolution profiles [30]: 263 
𝑓2 = 50 × log⁡{[1 +
1
𝑛
∑ (𝑅𝑡 − 𝑇𝑡
𝑛
𝑡=1 )




where 𝑛 is the number of dissolution time points, 𝑅𝑡 and 𝑇𝑡 are the dissolution value of the 265 
reference and test sample at the time 𝑡, respectively. 266 
 267 
The mathematical method of 𝑓2 has been adopted by many guidance, like Food and Drug 268 
Administration (FDA) and European Medicines Agency (EMEA), as a criterion for 269 
measurement of the similarity between in vitro dissolution profiles [31]. As the value of 𝑓2 270 
equals to 100 when the two profiles are identical and the value is 50 when an average variation 271 
of 10% at all determined time points, a public standard for 𝑓2 value between 50 and 100 can 272 
indicate the two dissolution profiles are similar, whereas the value of less than 50 can show the 273 
two profiles are different. 274 
 275 
2.6. Cell Studies of the Devices in Vitro with FLU Solution 276 
2.6.1. Preparation of Sponges Samples Loaded with Drug Solution 277 
As the sponge samples are very porous, it is easy for the drug solution penetrates the sponge 278 
and retained by the sponge. Three samples of each sponge formulation (diameter × thickness 279 
= 5 mm × 2 mm) were compressed gently in the drug solution until no air bubbles come out. 280 
After that, the sponge samples with drug solutions were taken out and leave them at room 281 
temperature. 282 
 283 
2.6.2. Cell Lines 284 
HeLa and Trex cells both stably express green fluorescent protein (GFP) constructs. Cell lines 285 
were maintained in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal 286 
calf serum (FCS), penicillin/streptomycin and L-Glutamine at 37°C and 5% CO2. 287 
 288 
2.6.3. Experimental Set-Up 289 
Substrates transferred to 12 well plates and sterilized with UV irradiation 30 min prior to adding 290 
cells. Cells were plated at a density of 0.4×105 on day 0. Day 1, substrates were transferred to 291 
new wells to avoid any effect of cell dissociation. Cells remaining cells were trypsinized using 292 




plated onto the transferred substrates in fresh media. Day 4, substrates were removed and 294 
discarded and remaining cells trypsinized, counted and discarded as before. Images were taken 295 
prior to trypsinisation. 296 
3. Results and Discussion 297 
3.1. Fabrication and Characterization of Magnetic PDMS Sponges 298 
Among all prepared magnetic PDMS sponges (Figure 3), 100 w/w% CI/PDMS sponge was 299 
selected for the scaffold in this experiment as it exhibited the most deformation tendency at the 300 
given reflux under certain magnetic fields. The underlying reasons being that the ferromagnetic 301 
particles were homogeneously distributed throughout the PDMS sponges as such it was enough 302 
to deform the sponges at a suitable extent to trigger drug release from the system. The lower or 303 
higher amount of CI particles in the formulation exhibited insufficient or excessive reflux in 304 
the experimental set-up, respectively. Based on the preliminary results, 100% w/w CI/PDMS 305 
formulation was selected for the additional studies.  306 
 307 
Figure 3. Photograph of the pure PDMS sponge cylinder, CI loaded PDMS cylinder and cube. 308 
 309 
3.2. Fabrication and Characterization of the Reservoir 310 
3.2.1. Printing the Device 311 
   The PLA filaments were transformed into reservoirs via a Robo R2 FDM 3D printer (Figure 312 
1C). The suitable size of the sponge cylinder was cut and subsequently installed into the PLA 313 
reservoir bottom before the top part assembling and drug loading. The reservoir could be 314 
opened later, meanwhile, both the reservoir and PDMS sponge cylinders could be washed 315 
completely and reutilized (Figure 1B). These printed reservoirs showed satisfactory mechanical 316 
properties. These two parts of the reservoir are white, non-friable, plastic-like and can be closed 317 




3.2.2. Characterization of 3D Printed Reservoirs 319 
The extruded PLA filament was smooth and uniform with a diameter of 0.403±0.001 mm. The 320 
value of 𝐸𝑟 (100.75 %) reduced the possibility of die swelling, which may cause uneven 321 
filament blocking the feed nozzle (ø=0.4 mm) of the printer. SEM analysis (Figure 4) 322 
confirmed that the printed reservoir has a layered structure as the printing was conducted in a 323 
layer-by-layer manner. 324 
 325 
Figure 4. SEM images of (A) PLA filaments, (B) the bottom surface of the reservoir, (C) the 326 
top surface of the reservoir, (D) the side surface of the reservoir. 327 
 328 
3.3. Assemble and Drug Loading of the TDDS 329 
The sponge cylinders with the diameter and height of 12.5 mm and 5mm respectively were cut 330 
carefully and loaded into the hollow space of the reservoir bottom. Then the two parts of the 331 
reservoir can be closed tightly (Figure 1E). 332 
 333 
After the pure PDMS sponge or the CI-loaded PDMS sponge was assembled into the reservoir, 334 
around 0.3 mL solution could be loaded into the device because of the strong water absorption 335 
of the sponge samples. The dose of drug loaded into the device could be calculated by analyzing 336 
the weight change (weight of solution) of the device before and after the drug loading process. 337 
The maximum concentration of the FLU solution was optimized at 25 mg/mL [27]. As a result, 338 




3.4. Dissolution Test under Sink Conditions 340 
It is assumed that the location of magnetic bar respect to the location of the reservoir containing 341 
sponge can deform sponge differently and this, in turn, releases the drug with the different 342 
pattern when compared to the release behaviour of the device without magnets (Figure 5). 343 
Some drug solutions can release from the small aperture gradually without magnets (Mode 2). 344 
When the magnet bar is contacted with the side part of the device, the magnetic sponge loaded 345 
with the drug solution can move close to the magnetic bar because of the magnetic field and 346 
drug solution is squeezed out through the small aperture (Mode 3). In contrast, the magnetic 347 
sponge and drug solution moves away from the aperture when the magnetic bar is at the bottom 348 
of the device, so only a little amount of drug solution will be released (Mode 1). To prove this 349 
hypothesis, dissolution tests under sink conditions were carried out.  350 
 351 
Figure 5. A schematic cross-section view diagram showing the release mechanism of the device 352 
with the utilization of the magnetic field from different directions (left: Mode 1, middle: Mode 353 









In vitro drug release profiles from the same drug-loaded device but with different utilizations 360 
of magnets are depicted in Figure 6. The dissolution test was carried out for 12 h, and the results 361 
showed that over 80% of the drug released in Model 3 within the first 720 min. 362 
  363 
When the device was standing on Magnet D (Model 1), the dissolution rate was faster than 364 
other models. The probable reasons may have been the drug solution could release from the 365 
small aperture because of the deformation caused by the magnetic field. In particular, the time 366 
at which 10%, 50%, 80% and 90% of the drug were dissolved (T10%, T50%, T80% and T90% 367 
respectively) are observed at <5, 20, 55 and 140 min (Figure 6). When Model 7 which the 368 
device was standing on Magnet B (the smaller magnetic field) and compared with Model 1 (the 369 
stronger magnetic field), the drug release was much faster from Model 1 (𝑓2 =40.58) mainly 370 
due to the more obvious deformation caused by a stronger magnetic field. 371 
 372 
However, the drug release from the device which was lying on the magnet (Model 5) is 373 
dramatically slow. The comparison of dissolution profiles of Model 1 with model 5 374 
demonstrated that the deformation of the magnetic sponge in Model 1 is more efficient than 375 
Model 5 because of the position of the small aperture and the size differences between the 376 
diameter and height of the sponge samples assembled in the reservoir (𝑓2 =9.71). 377 
    378 
Besides, there are also significant differences between Models 1 and 2 (𝑓2 =30.03), Models 2 379 
and 5 (𝑓2 =15.66). This indicates that the different utilizations of the external magnetic field 380 
have crucial influences on the dissolution behaviour of drug release from the device. The 381 
dissolution behaviours of the drug-loaded device are different in basket and paddle methods 382 
because of the obvious difference between Model 2 and 3 (𝑓2 = 30.03), Model 4 and 5 383 
(𝑓2 =50.56). 384 
    385 
To prove the small aperture on the top of the reservoir is the main pathway for drug-releasing, 386 
the device without any aperture was designed, fabricated and analyzed (Model 6) in the same 387 




the amount is much lower than that of Model 2. This indicates that the drug solution is mainly 389 
released from the small aperture. However, the slower drug release in Model 8 when compared 390 
with Model 5 indicates that the weaker magnetic field can release less drug in Mode 1. 391 
    392 
It can be concluded that the switching “on” state in the release pattern from the device can be 393 
triggered when the magnet is employed like Model 1, and the switching “off” drug-releasing 394 
of the device can also be realized when we change the position of the magnets like Model 8. 395 
Consequently, the release of drugs from this device can be controlled repeatedly and quickly. 396 
All these features make this novel implantable drug delivery device a promising candidate to 397 
tailor and control the release of therapeutic substances in local disease therapy. The device 398 
could be navigated to the target site in vivo wirelessly with the application of magnetic fields. 399 
With the development of this TDDS, the anticancer agent (FLU) could be navigated to the 400 
target site and released at an adjustable rate in accordance with patients’ specific conditions for 401 
minimizing adverse effects during cancer treatment. Herein, the bioavailability of FLU could 402 
be enhanced significantly. Furthermore, this device shows superior potential in hormone 403 
deficiencies and chronic pain treatments. Desirable doses of these drugs, like hormones and 404 
painkillers, can be released by loading these drug solutions of various concentrations into the 405 






Model  Basket/Paddle Magnet Mode  Aperture T10% T50% T80% T90% 
1 Paddle D 3 √ <5 min 20 min 55 min 120 min 
2 Paddle × 2 √ 25 min 120 min 240 min 340 min 
3 Basket × 4 √ 80 min 280 min 640 min - 
4 Basket D 1 √ 80 min -* -* - 
5 Paddle D 1 √ 80 min -* - - 
6 Paddle × 2 × 220 min -* - - 
7 Paddle B 3 √ <5 min 50 min 220 min 360 min 
8 Paddle B 1 √ 720 min - - - 
 409 
 410 
Figure 6. In vitro mean drug release profiles (±SD) (under sink condition) in PBS (pH 6.8) of 411 
device loaded with 25 mg/mL FLU solution (𝑛 = 3). Different models and the time at which 412 
10%, 50%, 80% and 90% of the drug were dissolved are clarified underneath the dissolution 413 
profiles for the comparison of drug release behaviours of the device.  414 
 415 
3.5. Cell Studies in vitro 416 
It is necessary to analyze the cell inhibition behaviour of FLU loaded 3D printed reservoir and 417 
sponge samples. The assessment of cell numbers of Trex cells was designed as follows. The 418 
cell numbers in Figure 7 (Group B1, B9 with B11, Group B2 with B10) display that these 419 




Trex cells to some extent, but the number of Trex cells still increased within 4 days because 421 
there are no FLU solution. Through comparing data of groups under the same conditions just 422 
except for applying magnetic fields (Group B9 with B10, Group B1 with B2, and Group B3 423 
with B4), it can be concluded that stronger magnet will lead to more drugs being released from 424 
the deformation of magnetic sponges and more obvious inhibition effects on Trex cell growth. 425 
Importantly, sponge samples loaded with a higher concentration of FLU solution (Group B3 426 
with B5, Group B4 with B6) present a stronger inhibition effect on Trex cells. The results 427 
showed that there is no difference between Group 7 and 8 and this is not surprising because the 428 
magnet would not trigger the release of drug solution loaded in the device when the magnets 429 
were placed at the bottom of the whole device as reflected by the results highlighted in the 430 
dissolution section. 431 
 432 
Group Magnet Sponge FLU Solution PLA Reservoir 
B1 B CI/PDMS=100 wt% × × 
B2 C CI/PDMS=100 wt% × × 
B3 B CI/PDMS=100 wt% 12.5 mg/mL  × 
B4 C CI/PDMS=100 wt% 12.5 mg/mL  × 
B5 B CI/PDMS=100 wt% 25 mg/mL  × 
B6 C CI/PDMS=100 wt% 25 mg/mL  × 
B7 × CI/PDMS=100 wt% 12.5 mg/mL  √ 
B8 B CI/PDMS=100 wt% 12.5 mg/mL  √ 
B9 B × × × 
B10 C × × × 
B11 B pure PDMS × × 
 433 
Figure 7. Numbers of Trex cells under different conditions. 3D printed PLA reservoir and 434 




clarification the composition for each group was added in the table attached to the figure). 436 
 437 
In summary, stronger magnetic fields can lead to larger deformations of CI-loaded PDMS 438 
sponge cylinders and a higher volume of drug solution will be released from the drug-loaded 439 
magnetic PDMS sponges. By adjusting the concentration of the drug solution, the dose of the 440 
drug could be changed. Because the prepared magnetic sponge sample can release a specific 441 
volume of drug solution under the same magnetic field, the lower loaded solution concentration 442 
can lead to the lower loaded dose of the drug. With the assembly of a 3D printed PLA reservoir, 443 
there will be no obvious difference of released dose of drug from the whole device between the 444 
device having magnets placed underneath and the device alone without magnets. 445 
 446 
Conclusion 447 
In this experiment, we designed and developed a novel implantable drug delivery device 448 
assembled from a magnetic PDMS sponge cylinder and a 3D-printed PLA reservoir to provide 449 
a triggerable and remotely controllable system for on-demand drug delivery in localized 450 
disease treatment. This device utilizes different extrinsic magnetic fields for offering a tunable 451 
force to trigger drug release through reversible magnetic sponge deformations. The geometric 452 
shape and dimensions of the reservoir could be adjusted easily through FDM 3D printing 453 
technology according to the requirement of patients. In addition, the drug-releasing dose and 454 
timing can be reliably and flexibly controlled by different applications of the magnetic field to 455 
fit the prescribed needs. Furthermore, this device has the potential to be optimized as a safe 456 
and long-term implant because of its large drug loading ability. It can be the key component of 457 
a multi-functional, implantable and smart drug delivery system for the controlled release of 458 
therapeutic substances to avoid frequent injection or various sophisticated dosing regimens. In 459 
the future, combining the device with i.e. sensing system can also offer protection for 460 
biosensors because biofouling and exposure to the body may lead to the failure of biosensors 461 
in vivo. 462 
 463 
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